Welcome to our dedicated page for Evaxion Biotech A/S American Depositary Share news (Ticker: EVAX), a resource for investors and traders seeking the latest updates and insights on Evaxion Biotech A/S American Depositary Share stock.
Evaxion Biotech A/S (symbol: EVAX) is a clinical-stage biotechnology company founded in 2008 with the mission to address some of the most significant global health challenges using artificial intelligence (AI). The company has developed robust platforms for creating novel vaccines and therapies. Evaxion's primary AI platforms, PIONEER and EDEN, utilize advanced in silico tools including big data, AI, and supercomputing to predict, rank, and optimize epitopes and antigens that stimulate highly protective immune responses against cancers and infectious diseases.
Evaxion's EDEN platform focuses on the rapid discovery of new antigens eliciting cross-protective immune responses against bacterial pathogens. On the other hand, the PIONEER platform identifies epitopes of mutated proteins to activate the body's natural immune responses. Additionally, the company has developed two more AI platforms, RAVEN and ObsERV, to further enhance its drug development pipeline.
The company's leading product candidates include EVX-01 and EVX-02, which are under development for cancer treatment, as well as EVX-03, a pre-clinical candidate for non-small-cell lung cancer (NSCLC). With a strong focus on AI-driven drug discovery and development, Evaxion aims to create innovative immunotherapies with improved efficacy for patients with unmet medical needs.
Recent news highlights key company activities, such as:
- A replay of the R&D Day presentations is available on the company's website.
- Information about the EVX-01 Phase 2 clinical trial.
- The company resolved a Nasdaq equity deficiency issue stemming from the IFRS accounting treatment of investor warrants.
To learn more about Evaxion Biotech A/S and its innovative AI-driven approaches, please visit Evaxion Biotech.
Rhea-AI Summary
Evaxion Biotech A/S (NASDAQ: EVAX) has announced the pricing of a public offering of 3,750,000 of its American Depositary Shares (ADSs) and warrants to purchase up to 3,750,000 ADSs at a combined public offering price of $4.00 per ADS. MSD Global Health Innovation Fund, a shareholder since December 2023, is also participating in this offering.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
17.05%
Tags
-
Rhea-AI Summary
Evaxion Biotech A/S (NASDAQ: EVAX) is expanding its commitment to developing tailored cancer vaccines by targeting a novel category of AI-identified tumor antigens, named Endogenous Retroviruses (ERVs). This AI-Immunology™ powered vaccine concept offers the potential to provide treatment solutions to cancer patients unresponsive to conventional cancer immunotherapy. The company aims to generate Proof-of-Concept data by the second half of 2024, with a focus on delivering treatment solutions to previously unresponsive cancer patients. Evaxion's Chief Scientific Officer, Birgitte Rønø, expresses optimism about the significant potential of ERV-based vaccines and the company's commitment to improving healthcare through innovative and AI-powered approaches. The company also presented recent insights at the American Society of Hematology (ASH) Annual Meeting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
113.43%
Tags
-
Rhea-AI Summary
Evaxion Biotech A/S (NASDAQ: EVAX) has announced a change in the ratio of its American Depositary Shares (ADSs) to its ordinary shares, with the new ratio of 1 ADS representing 10 ordinary shares. This change, effective from January 22, 2024, is intended to support liquidity and enable the company to regain compliance with the Nasdaq minimum bid price requirement. The ADS Ratio Change affects all shareholders uniformly and will not alter any shareholder’s percentage interest in the Company’s equity. However, no assurance has been given regarding the proportionate increase in the ADS trading price after the change.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
36.3%
Tags
Rhea-AI Summary
Evaxion Biotech A/S (NASDAQ: EVAX) plans to change the ratio of its American Depositary Shares (ADSs) to its ordinary shares from 1:1 to 1:10. This change is expected to become effective on Jan. 15, 2024. Evaxion is a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.05%
Tags
-
Rhea-AI Summary
Evaxion Biotech A/S (NASDAQ: EVAX) closes private placement with gross proceeds of $5.3 million, including a 25% investment from MSD Global Health Innovation Fund. The private placement involved the sale of 9,726,898 ordinary shares represented by ADSs and accompanying warrants. The company plans to use the proceeds for working capital and general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.05%
Tags
-
Rhea-AI Summary
Evaxion Biotech A/S (NASDAQ: EVAX) announced its refined strategy with increased focus on value realization via partnerships based on the AI-Immunology™ platform. The company reported solid progress with two partnerships announced in Q3 and proof-of-principle for Evaxion’s proprietary responder model. They also priced a bridge financing round expected to raise $5.3 million, aiming to fund operations until March 2024. The company aims to fund 2024 cash burn with income from business development activities, expecting cash burn at the level of $14 million in 2024. Evaxion's CEO highlighted the refined strategy's focus on value realization and reduced cash burn, emphasizing strong business execution based on the new strategy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.91%
Tags
Rhea-AI Summary
Evaxion Biotech A/S (NASDAQ: EVAX) announces a private placement financing to raise gross proceeds of approximately $5.3 million, with MSD Global Health Innovation Fund (MSD GHI) contributing 25% of the total offering amount. The Private Placement includes participation from existing and new shareholders, with significant involvement from the Company’s management and board of directors. The Private Placement involves the issuance and sale of 9,726,898 of the Company’s ordinary shares and accompanying warrants at a purchase price of $0.544 per Ordinary Share for an aggregate purchase price of $5.3 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.96%
Tags
-
Rhea-AI Summary
Evaxion Biotech (EVAX) presents breakthrough achievement in precision cancer vaccines at the 65th ASH Annual Meeting
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.22%
Tags
-
Rhea-AI Summary
Evaxion Biotech A/S (NASDAQ: EVAX) presents a novel AI model at the Biomarkers & Precision Oncology Europe conference in Berlin, Germany, designed to predict patient responses to cancer immunotherapy. The model aims to improve patient outcomes, reduce healthcare costs, and is scalable for broader applications. Evaxion plans to pursue a partnership-based approach towards a commercial offering.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.34%
Tags
News
Rhea-AI Summary
Evaxion Biotech A/S (NASDAQ: EVAX) is hosting an online webinar on November 8th featuring Professor Adnan Khattak, the principal investigator of the EVX-01 clinical trial. EVX-01 is Evaxion's lead clinical asset based on its AI-Immunology™ platform. The webinar will discuss the promising results of the Phase 1 trial and provide an update on the Phase 2 trial, which appears to confirm the benefits of this innovative immunotherapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.63%
Tags
FAQ
What is the current stock price of Evaxion Biotech A/S American Depositary Share (EVAX)?
The current stock price of Evaxion Biotech A/S American Depositary Share (EVAX) is $1.37 as of November 21, 2024.
What is the market cap of Evaxion Biotech A/S American Depositary Share (EVAX)?
The market cap of Evaxion Biotech A/S American Depositary Share (EVAX) is approximately 7.9M.
What does Evaxion Biotech A/S specialize in?
Evaxion Biotech A/S specializes in developing novel vaccines and therapies using artificial intelligence to solve significant health challenges.
What are the main AI platforms used by Evaxion Biotech?
Evaxion Biotech uses the PIONEER, EDEN, RAVEN, and ObsERV AI platforms for drug discovery and development.
What are Evaxion's leading product candidates?
Evaxion's leading product candidates include EVX-01 and EVX-02 for cancer treatment and EVX-03 for non-small-cell lung cancer.
What recent developments have taken place at Evaxion Biotech?
Recent developments include a replay of the R&D Day presentations, information about the EVX-01 Phase 2 clinical trial, and a resolution of a Nasdaq equity deficiency issue.
When was Evaxion Biotech A/S founded?
Evaxion Biotech A/S was founded in 2008.
How does the EDEN platform contribute to Evaxion's research?
The EDEN platform aids in the rapid discovery of novel antigens that elicit cross-protective immune responses against bacterial pathogens.
What is PIONEER platform's role in Evaxion's operations?
The PIONEER platform identifies epitopes of mutated proteins to activate the body's natural immune responses, particularly in cancer treatments.
What kind of financial challenges has Evaxion recently addressed?
Evaxion addressed a Nasdaq equity deficiency issue related to the IFRS accounting treatment of investor warrants by converting the exercise price from USD to DKK.
Where can I find more information about Evaxion's recent activities?
More information about Evaxion's recent activities can be found on their official website at www.evaxion-biotech.ai.
What is the mission of Evaxion Biotech A/S?
The mission of Evaxion Biotech A/S is to tackle significant global health challenges using artificial intelligence to develop novel vaccines and immunotherapies.
Evaxion Biotech A/S American Depositary Share